Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439140 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00439140 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 41 participants.
The verdict
NCT00439140, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
Interventions
- DRUG Normal Saline (Placebo)
- BIOLOGICAL botulinum toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439140
The ClinicalTrials.gov registry entry for NCT00439140 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline (Placebo) is the first listed.
NCT00439140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439140 about?
NCT00439140 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder". This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
What is the current status of trial NCT00439140?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2007-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00439140?
The interventions under investigation include: Normal Saline (Placebo) (DRUG), botulinum toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00439140?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.